Danazol therapy in haemophilia.

Heaton Dc, Wyld Pj, Conder Jl
In: The New Zealand medical journal · 1986 · vol. 99(798) , pp. 185–7 · PMID:3517712 · W2402505524
article OA: closed CC0 ⤵ 2 in-corpus citations
View on OpenAlex View on PubMed
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-12 ⓘ

Danazol therapy shortened APTT and ECLT in hemophilia patients but did not consistently alter factor levels or improve bleeding tendency.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Three patients with severe haemophilia A and one patient with moderately severe Christmas disease were given danazol and placebo in a double blind cross over trial to study the effects on haemostatic variables and bleeding tendency. In each case there was a shortening of the activated partial thromboplastin time (APTT) and euglobulin clot lysis time (ECLT) during danazol therapy but factor VIII and IX levels did not show any consistent change and there was no improvement in the bleeding tendency.

My notes (saved in your browser only)

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cited by (2)

Cited by (2)

Source provenance

openalex
last seen: 2026-05-10T17:55:59.275987+00:00
License: CC0 · commercial use OK